40 results on '"Muss, H"'
Search Results
2. P16INK4aexpression after chemotherapy in older women with early-stage breast cancer.
3. The relationship between age and survival outcomes for eribulin in metastatic breast cancer.
4. The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women.
5. A randomized trial of atorvastatin versus placebo in women at high risk for breast cancer.
6. Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients
7. Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy
8. Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience
9. Patient preferences for adjuvant treatment of early-stage breast cancer
10. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG
11. Phase I/II feasibility trial of adjuvant dose-dense (DD) docetaxel/epirubicin/cyclophosphamide (TEC) in stage II/III breast cancer
12. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC
13. Cyclin D1 (CD1), interleukin-6 (IL-6), Ki67, transforming growth factor beta type II receptor, HER-2 and prediction of relapse in women with early stage breast cancer (BC) taking tamoxifen
14. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients
15. The role of HER-2 + Topo IIα amplification in predicting benefit from CAF dose escalation-CALGB 8541
16. Development of a comprehensive geriatric assessment (CGA) measure for older patients (Pts) with cancer: A feasibility study
17. A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome
18. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer
19. A randomized controlled trial of an educational program to improve accrual of older persons to cancer treatment protocols: CALGB 360001
20. Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen
21. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.
22. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
23. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.
24. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
25. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
26. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
27. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and...
28. Breast cancer in the elderly.
29. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association.
30. Adjuvant irradiation following mastectomy: where are we?
31. Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer.
32. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
33. Secondary malignancies of the penis and epididymis: a case report and review of the literature.
34. A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer.
35. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.
36. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
37. Improvement of long-term survival in extensive small-cell lung cancer.
38. Single agent vincristine by infusion in refractory multiple myeloma.
39. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
40. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.